Adiponectin Plasma Levels and Albuminuria in Patients with Type 2 Diabetes and Different Stages of Diabetic Kidney DiseaseAnastasia Georgoulidou1*, Athanasios Roumeliotis1, Stefanos Roumeliotis1, Ilias Thodis1, Vangelis Manolopoulos2, Pavlos Malindretos3, Kostas Mavromatidis4 and Ploumis Passadakis1
- *Corresponding Author:
- Anastasia Georgoulidou
General Hospital of Komotini, Renal Department
Sismanoglou 45, Komotini
Rodopi 69132, Greece
E-mail: [email protected]
Received Date: January 12, 2017; Accepted Date: January 24, 2017; Published Date: January 25, 2017
Citation: Georgoulidou A, Roumeliotis A, Roumeliotis S, Thodis I, Manolopoulos V, et al. (2017) Adiponectin Plasma Levels and Albuminuria in Patients with Type 2 Diabetes and Different Stages of Diabetic Kidney Disease. J Nephrol Ther 7: 285. doi:10.4172/2161-0959.1000285
Copyright: © 2017 Georgoulidou A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Adiponectin is an inflammatory cytokine produced by adipose tissue and its protective role has been recognized in the pathogenesis of obesity. A lower concentration in obesity patients is noted, in conditions of resistance to insulin, diabetes mellitus, and CKD. Patients with type 2 diabetes mellitus have a potential risk of atherosclerosis, while low concentrations of adiponectin are considered as predictor for the occurrence of complications in patients with type 2 diabetes. The aim of this study was to investigate in patients with type 2 diabetes mellitus with and without diabetic nephropathy the correlation of adiponectin levels and CKD stage or degree of albuminuria. We studied 119 patients with type 2 diabetes mellitus with different stage of renal function, the levels of plasma adiponectin, and the BMI. A statistically significant difference of plasma adiponectin levels was noted between the initial and end stages of CKD, the highest levels seen in ESKD patients. Also, the levels of adiponectin were elevated in patients with greater albuminuria (statistically significant difference between groups 1 and 3, p=0.05). The levels of adiponectin were found to decrease with increasing the stage of obesity (ANOVA, p<0.05). Finally, the group of patients receiving glitazones had higher plasma adiponectin levels compared to those not receiving. It concluded that the levels of adiponectin increase with the deterioration of renal function and with enhancement of albuminuria, while decreasing as the stage of obesity worsens. The administration of glitazones was associated with increased plasma levels of adiponectin.